BR0317659A - Derivados de pirazol como inibidores de fator xa - Google Patents

Derivados de pirazol como inibidores de fator xa

Info

Publication number
BR0317659A
BR0317659A BR0317659-2A BR0317659A BR0317659A BR 0317659 A BR0317659 A BR 0317659A BR 0317659 A BR0317659 A BR 0317659A BR 0317659 A BR0317659 A BR 0317659A
Authority
BR
Brazil
Prior art keywords
factor
compounds
formula
inhibitors
vila
Prior art date
Application number
BR0317659-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Marc Nazare
Volkmar Wehner
David William Will
Hans Matter
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02028915A external-priority patent/EP1433788A1/en
Priority claimed from EP03011308A external-priority patent/EP1479678A1/en
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0317659A publication Critical patent/BR0317659A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0317659-2A 2002-12-23 2003-12-10 Derivados de pirazol como inibidores de fator xa BR0317659A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02028915A EP1433788A1 (en) 2002-12-23 2002-12-23 Pyrazole-derivatives as factor Xa inhibitors
EP03011308A EP1479678A1 (en) 2003-05-19 2003-05-19 Pyrazole-derivatives as factor xa inhibitors
PCT/EP2003/013979 WO2004056815A1 (en) 2002-12-23 2003-12-10 PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
BR0317659A true BR0317659A (pt) 2005-12-06

Family

ID=32683809

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317659-2A BR0317659A (pt) 2002-12-23 2003-12-10 Derivados de pirazol como inibidores de fator xa

Country Status (13)

Country Link
EP (1) EP1581523B1 (enExample)
JP (1) JP4585448B2 (enExample)
AR (1) AR042648A1 (enExample)
AT (1) ATE444292T1 (enExample)
AU (1) AU2003292218A1 (enExample)
BR (1) BR0317659A (enExample)
CA (1) CA2511321A1 (enExample)
DE (1) DE60329529D1 (enExample)
IL (1) IL169323A0 (enExample)
MX (1) MXPA05006200A (enExample)
PE (1) PE20040925A1 (enExample)
TW (1) TW200505914A (enExample)
WO (1) WO2004056815A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
DE102004047255A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Prolinderivate
AU2005299693B2 (en) 2004-10-26 2012-07-05 Janssen Pharmaceutica, N.V. Factor Xa compounds
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
CN101087762A (zh) * 2004-10-29 2007-12-12 先灵公司 作为抗病毒剂的取代的5-甲酰胺吡唑和[1,2,4]三唑
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
EP1724269A1 (en) * 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
MX2008000141A (es) * 2005-06-27 2008-04-07 Exelixis Inc Moduladores de lxr basados en imidazol.
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5560202B2 (ja) * 2007-12-26 2014-07-23 サノフイ P2y12拮抗薬としてのピラゾール−カルボキサミド誘導体
JP5504171B2 (ja) * 2007-12-26 2014-05-28 サノフイ P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
AU2009240643B2 (en) * 2008-04-23 2014-03-06 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
AR079967A1 (es) 2010-01-26 2012-02-29 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
TWI523844B (zh) 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之3-雜芳醯基胺基-丙酸衍生物及其作為藥物之用途
US8669370B2 (en) 2011-01-26 2014-03-11 Sanofi Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
CN103827098B (zh) 2011-07-26 2016-06-15 赛诺菲 取代的3-(噻唑-4-羰基)-或者3-(噻唑-2-羰基)-氨基丙酸衍生物及其作为药物的用途
WO2013014204A2 (en) 2011-07-26 2013-01-31 Sanofi 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US20130123325A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
ES2702182T3 (es) * 2013-03-15 2019-02-27 Verseon Corp Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
AU2014243070B2 (en) 2013-03-28 2017-12-21 Sanofi Biaryl-propionic acid derivatives and their use as pharmaceuticals
WO2014154726A1 (en) 2013-03-28 2014-10-02 Sanofi Biaryl-propionic acid derivatives and their use as pharmaceuticals
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
SG11201706411YA (en) 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP1045846B1 (en) * 1997-11-28 2003-05-02 Lg Chemical Limited Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
JP2001526268A (ja) * 1997-12-22 2001-12-18 デュポン ファーマシューティカルズ カンパニー Xa因子阻害剤としての、オルト−置換P1を有する、窒素含有複素環式芳香族化合物
WO2000039131A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company Nitrogen containing heterobicycles as factor xa inhibitors
MXPA02000537A (es) * 1999-07-16 2004-09-10 Bristol Myers Squibb Pharma Co Heterobiciclos que contienen nitrogeno como inhibidores del factor xa.
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
NZ517828A (en) * 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
CA2409762A1 (en) * 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
CA2444571A1 (en) * 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1, 4, 5, 6-tetrahydropyrazolo-¬3, 4-c|-pyridin-7-ones as factor xa inhi bitors

Also Published As

Publication number Publication date
EP1581523A1 (en) 2005-10-05
AR042648A1 (es) 2005-06-29
WO2004056815A1 (en) 2004-07-08
CA2511321A1 (en) 2004-07-08
AU2003292218A1 (en) 2004-07-14
DE60329529D1 (de) 2009-11-12
IL169323A0 (en) 2007-07-04
MXPA05006200A (es) 2005-08-19
EP1581523B1 (en) 2009-09-30
TW200505914A (en) 2005-02-16
JP2006511608A (ja) 2006-04-06
JP4585448B2 (ja) 2010-11-24
PE20040925A1 (es) 2004-12-24
ATE444292T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
BR0317659A (pt) Derivados de pirazol como inibidores de fator xa
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BR0116473A (pt) Derivados de oxibenzamidas como inibidores de fator xa
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
CL2004001074A1 (es) COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA,
BRPI0410430A (pt) derivados de indazol como inibidores de fato xa
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
BR0111264A (pt) Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
BR0015186A (pt) N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as
AU2002325238A1 (en) Urea derivatives with antiproteolytic activity
BR0011461A (pt) Inibidores do fator viia
BR0317003A (pt) Derivados de imidazol como inibidores do fator xa
ATE394396T1 (de) Triazolderivate als faktor-xa-inhibitoren
BRPI0410446A (pt) derivados de benzimidazol como inibidores de fator xa
BRPI0410429A (pt) derivados de azaindol como inibidores do fator xa
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.